The 2012 Briganti nomogram predicts disease progression in surgically treated intermediate-risk prostate cancer patients with favorable tumor grade group eventually associated with some adverse factors.

导出 LinkOut

翻译打印收藏纠错

作者： Antonio Benito,Porcaro ^[1] ; Rossella,Orlando ^[2] ; Andrea,Panunzio ^[3] ; Alessandro,Tafuri ^[3] ; Alberto,Baielli ^[2] ; Francesco,Artoni ^[2] ; Francesca,Montanaro ^[2] ; Sebastian,Gallina ^[2] ; Alberto,Bianchi ^[2] ; Giovanni,Mazzucato ^[2] ; Emanuele,Serafin ^[2] ; Alessandro,Veccia ^[2] ; Michele,Boldini ^[2] ; Lorenzo Pierangelo,Treccani ^[2] ; Riccardo,Rizzetto ^[2] ; Matteo,Brunelli ^[4] ; Filippo,Migliorini ^[2] ; Riccardo,Bertolo ^[2] ; Maria Angela,Cerruto ^[2] ; Alessandro,Antonelli ^[2]

作者单位： Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. drporcaro@yahoo.com. ^[1] Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. ^[2] Department of Urology, Vito Fazzi Hospital, Lecce, Italy. ^[3] Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. ^[4]

关键词 Disease progression Lymph node dissection Minimally invasive surgical procedures Nomogram Prostate cancer Recurrence